Corcept Therapeutics (CORT) Competitors $69.24 -0.13 (-0.19%) As of 03:36 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock CORT vs. ANVS, RPRX, JAZZ, PRGO, SUPN, PCRX, NKTR, OMER, ASMB, and CPIXShould you be buying Corcept Therapeutics stock or one of its competitors? The main competitors of Corcept Therapeutics include Annovis Bio (ANVS), Royalty Pharma (RPRX), Jazz Pharmaceuticals (JAZZ), Perrigo (PRGO), Supernus Pharmaceuticals (SUPN), Pacira BioSciences (PCRX), Nektar Therapeutics (NKTR), Omeros (OMER), Assembly Biosciences (ASMB), and Cumberland Pharmaceuticals (CPIX). These companies are all part of the "medical" sector. Corcept Therapeutics vs. Its Competitors Annovis Bio Royalty Pharma Jazz Pharmaceuticals Perrigo Supernus Pharmaceuticals Pacira BioSciences Nektar Therapeutics Omeros Assembly Biosciences Cumberland Pharmaceuticals Annovis Bio (NYSE:ANVS) and Corcept Therapeutics (NASDAQ:CORT) are both medical companies, but which is the better business? We will contrast the two businesses based on the strength of their analyst recommendations, risk, valuation, profitability, earnings, institutional ownership, dividends and media sentiment. Which has more risk and volatility, ANVS or CORT? Annovis Bio has a beta of 1.65, meaning that its stock price is 65% more volatile than the S&P 500. Comparatively, Corcept Therapeutics has a beta of 0.29, meaning that its stock price is 71% less volatile than the S&P 500. Do insiders and institutionals hold more shares of ANVS or CORT? 15.8% of Annovis Bio shares are owned by institutional investors. Comparatively, 93.6% of Corcept Therapeutics shares are owned by institutional investors. 20.8% of Annovis Bio shares are owned by company insiders. Comparatively, 20.8% of Corcept Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth. Which has preferable valuation & earnings, ANVS or CORT? Corcept Therapeutics has higher revenue and earnings than Annovis Bio. Annovis Bio is trading at a lower price-to-earnings ratio than Corcept Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAnnovis BioN/AN/A-$24.59M-$2.04-1.13Corcept Therapeutics$675.04M10.81$141.21M$1.1361.27 Do analysts rate ANVS or CORT? Annovis Bio currently has a consensus target price of $17.33, suggesting a potential upside of 650.69%. Corcept Therapeutics has a consensus target price of $134.50, suggesting a potential upside of 94.26%. Given Annovis Bio's higher probable upside, analysts plainly believe Annovis Bio is more favorable than Corcept Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Annovis Bio 0 Sell rating(s) 2 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.60Corcept Therapeutics 0 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 3.00 Is ANVS or CORT more profitable? Corcept Therapeutics has a net margin of 18.51% compared to Annovis Bio's net margin of 0.00%. Corcept Therapeutics' return on equity of 20.10% beat Annovis Bio's return on equity.Company Net Margins Return on Equity Return on Assets Annovis BioN/A -206.01% -158.26% Corcept Therapeutics 18.51%20.10%16.20% Does the media prefer ANVS or CORT? In the previous week, Annovis Bio had 1 more articles in the media than Corcept Therapeutics. MarketBeat recorded 12 mentions for Annovis Bio and 11 mentions for Corcept Therapeutics. Corcept Therapeutics' average media sentiment score of 0.45 beat Annovis Bio's score of -0.42 indicating that Corcept Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Annovis Bio 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Neutral Corcept Therapeutics 7 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral SummaryCorcept Therapeutics beats Annovis Bio on 11 of the 14 factors compared between the two stocks. Get Corcept Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for CORT and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding CORT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CORT vs. The Competition Export to ExcelMetricCorcept TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$7.29B$2.64B$5.77B$9.91BDividend YieldN/A49.35%6.67%4.51%P/E Ratio61.2023.3175.7426.65Price / Sales10.81740.37557.21121.56Price / Cash57.44169.7737.1158.92Price / Book10.675.4611.446.07Net Income$141.21M$32.95M$3.28B$266.32M7 Day Performance-0.69%2.15%0.63%0.06%1 Month Performance-1.72%7.14%6.89%3.90%1 Year Performance103.04%0.50%59.40%23.68% Corcept Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CORTCorcept Therapeutics4.8599 of 5 stars$69.24-0.2%$134.50+94.3%+100.4%$7.29B$675.04M61.20300Insider TradeANVSAnnovis Bio2.3566 of 5 stars$2.32flat$18.00+675.9%-73.0%$45.21MN/A-1.143Analyst ForecastAnalyst RevisionRPRXRoyalty Pharma4.9769 of 5 stars$35.98+1.0%$48.00+33.4%+26.1%$20.98B$2.31B20.8080Positive NewsJAZZJazz Pharmaceuticals4.7052 of 5 stars$127.75+1.3%$178.67+39.9%+17.8%$7.75B$4.07B-18.982,800Insider TradePRGOPerrigo4.9364 of 5 stars$23.77+0.0%$33.00+38.9%-18.3%$3.27B$4.33B-40.978,379SUPNSupernus Pharmaceuticals3.2265 of 5 stars$45.12-0.6%$43.00-4.7%+29.8%$2.53B$661.82M39.23580Positive NewsPCRXPacira BioSciences3.1422 of 5 stars$26.67-0.7%$30.83+15.6%+76.6%$1.20B$700.97M-9.59720News CoveragePositive NewsNKTRNektar Therapeutics3.9744 of 5 stars$29.86+1.8%$88.33+195.8%+93.4%$567.94M$98.43M-3.39220News CoverageOMEROmeros3.7895 of 5 stars$4.16-1.7%$18.00+332.7%+3.5%$283.11MN/A-1.97210Analyst ForecastASMBAssembly Biosciences3.3145 of 5 stars$24.70-3.1%$38.67+56.5%+40.4%$189.45M$28.52M-4.43100Short Interest ↑CPIXCumberland Pharmaceuticals0.8179 of 5 stars$3.49+0.6%N/A+185.9%$52.21M$37.87M-15.8680Positive News Related Companies and Tools Related Companies Annovis Bio Competitors Royalty Pharma Competitors Jazz Pharmaceuticals Competitors Perrigo Competitors Supernus Pharmaceuticals Competitors Pacira BioSciences Competitors Nektar Therapeutics Competitors Omeros Competitors Assembly Biosciences Competitors Cumberland Pharmaceuticals Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:CORT) was last updated on 9/5/2025 by MarketBeat.com Staff From Our PartnersWhy Trump’s “Smart Dollar” could rewrite the rulesMUST SEE: Donald Trump's Radical Overhaul of the U.S. Dollar Congress just approved President Trump's lates...Stansberry Research | Sponsored“Sell Nvidia before earnings”Eric Fry just went live with one of his most controversial calls yet: “Sell Nvidia.” While Wall Street has bee...InvestorPlace | SponsoredHow “Trump’s New Dollar” Could Impact Your WealthPresident Trump just signed a game-changing law… That could soon upgrade the U.S. dollar in your checking a...Brownstone Research | SponsoredForget Tesla — This Tiny AI Stock Is Musk’s Real PlayWhile Wall Street focused on Tesla’s earnings, Elon Musk was quietly building a supercomputer so powerful it c...Behind the Markets | SponsoredThis Coin Could Explode, and it’s Hiding in Plain Sight!The #1 coin with skyrocket potential right now... Sometimes the biggest opportunities are hiding in plain s...Crypto 101 Media | SponsoredRetire Comfortably with These New Monthly Income ETFs?Too many retirees lie awake at night, worried their savings won’t last. Traditional advice and tiny returns ju...Investors Alley | SponsoredWhat's the Best Way to Lower RMD Taxes?Turning 73 triggers a key IRS rule: you must begin taking required minimum distributions (RMDs) from certain r...SmartAsset | SponsoredWarren Buffett Issues Cryptic Warning on U.S. DollarImagine a bull market so powerful, every single investor became a millionaire. Not by finding the next NVIDIA ...Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Corcept Therapeutics Incorporated Please log in to your account or sign up in order to add this asset to your watchlist. Share Corcept Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
